As the year wraps up, investors are not taking the foot off the
pedal when it comes to filing 13Ds. All the recent concerns
about Chinese small caps did not prevent private equity firm
Warburg Pincus from adding on to its sizable stake in China
Biologic (Nasdaq:CBPO), a maker of plasma based pharmaceutical
and other related products. Warburg owns over 6 million shares,
or over 24%. (For related reading, see Digging Into 13D
Disclosures.)   Icahn's Newest Drama Carl Icahn is back in the
middle of an activist tussle after his publicized attempt to
seize control of consumer products company Clorox (NYSE:CLX)
failed. This time, the situation involves trucking and defense
products manufacturers Navistar (NYSE:NAV) and Oshkosh
(NYSE:OSK). Icahn happens to be a large shareholder in both
companies. Yet hedge fund Owl Creek Asset Management, which owns
8.5% of Navistar, has publicly expressed concern over the
possibility that Icahn would want to combine Navistar and
Oshkosh. Share prices in both companies have been hi